L T van der Heijden1,2, P Mian3,4, J Hias5, B C M de Winter6, J Tournoy7,8, L Van der Linden5,9, D Tibboel1, K Walgraeve5, J Flamaing7,8, B C P Koch6, K Allegaert6,9,10, I Spriet5,9. 1. Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 2. Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. 3. Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. p.mian@umcg.nl. 4. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. p.mian@umcg.nl. 5. Pharmacy Department, University Hospitals Leuven, Leuven, Belgium. 6. Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands. 7. Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. 8. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium. 9. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 10. Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Abstract
INTRODUCTION: Paracetamol pharmacokinetics (PK) is highly variable in older fit adults after intravenous administration. Frailty and oral administration likely result in additional variability. The aim was to determine oral paracetamol PK and variability in geriatric inpatients. METHODS: A population PK analysis, using NONMEM 7.2, was performed on 245 paracetamol samples in 40 geriatric inpatients (median age 87 [range 80-95] years, bodyweight 66.4 [49.3-110] kg, 92.5% frail [Edmonton Frail Scale]). All subjects received paracetamol 1000 mg as tablet (72.5%) or granulate (27.5%) three times daily. Simulations of dosing regimens (1000 mg every 6 hours [q6h] or q8h) were performed to determine target attainment, using mean steady-state concentration (Css-mean) of 10 mg/L as target. RESULTS: A one-compartment model with first order absorption and lag time best described the data. The inter-individual variability was high, with absorption rate constant containing the highest variability. The inter-individual variability could not be explained by covariates. Simulations of 1000 mg q6h and q8h resulted in a Css-mean of 10.8 [25-75th percentiles 8.2-12.7] and 8.13 [6.3-9.6] mg/L, respectively, for the average geriatric inpatient. The majority of the population remained off-target (22.2% [q6h] and 52.2% [q8h] <8 mg/L; 31.3 [q6h] and 7.6% [q8h] >12 mg/L). CONCLUSION: A population of average geriatric inpatients achieved target Css-mean with paracetamol 1000 mg q6h, while q8h resulted in underexposure for the majority of them. Due to high unexplained variability, a relevant proportion remained either above or below the target concentration of 10 mg/L. Research focusing on PK, efficacy and safety is needed to recommend dosing regimens.
INTRODUCTION: Paracetamol pharmacokinetics (PK) is highly variable in older fit adults after intravenous administration. Frailty and oral administration likely result in additional variability. The aim was to determine oral paracetamol PK and variability in geriatric inpatients. METHODS: A population PK analysis, using NONMEM 7.2, was performed on 245 paracetamol samples in 40 geriatric inpatients (median age 87 [range 80-95] years, bodyweight 66.4 [49.3-110] kg, 92.5% frail [Edmonton Frail Scale]). All subjects received paracetamol 1000 mg as tablet (72.5%) or granulate (27.5%) three times daily. Simulations of dosing regimens (1000 mg every 6 hours [q6h] or q8h) were performed to determine target attainment, using mean steady-state concentration (Css-mean) of 10 mg/L as target. RESULTS: A one-compartment model with first order absorption and lag time best described the data. The inter-individual variability was high, with absorption rate constant containing the highest variability. The inter-individual variability could not be explained by covariates. Simulations of 1000 mg q6h and q8h resulted in a Css-mean of 10.8 [25-75th percentiles 8.2-12.7] and 8.13 [6.3-9.6] mg/L, respectively, for the average geriatric inpatient. The majority of the population remained off-target (22.2% [q6h] and 52.2% [q8h] <8 mg/L; 31.3 [q6h] and 7.6% [q8h] >12 mg/L). CONCLUSION: A population of average geriatric inpatients achieved target Css-mean with paracetamol 1000 mg q6h, while q8h resulted in underexposure for the majority of them. Due to high unexplained variability, a relevant proportion remained either above or below the target concentration of 10 mg/L. Research focusing on PK, efficacy and safety is needed to recommend dosing regimens.
Authors: Antti Liukas; Kristiina Kuusniemi; Riku Aantaa; Petri Virolainen; Mikko Niemi; Pertti J Neuvonen; Klaus T Olkkola Journal: Clin Pharmacokinet Date: 2011-02 Impact factor: 6.447
Authors: Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick Journal: Eur J Clin Pharmacol Date: 2014-02-14 Impact factor: 2.953
Authors: Karel Allegaert; Klaus T Olkkola; Katie H Owens; Marc Van de Velde; Monique M de Maat; Brian J Anderson Journal: BMC Anesthesiol Date: 2014-09-13 Impact factor: 2.217